Waldencast Reports Flat Revenue Amid Strategic Shifts
Event summary
- Waldencast reported FY 2025 net revenue of $272.1 million, flat compared to FY 2024.
- Obagi Medical saw accelerated growth driven by international demand and U.S. direct-to-consumer success.
- Milk Makeup experienced a year-on-year decline in overall net revenue due to softer international consumption.
- Waldencast sold the Obagi Japan trademark rights for $82.5 million, using $77.5 million for debt repayment.
The big picture
Waldencast's flat revenue highlights the challenges of balancing brand transformation with financial discipline. The company's strategic shifts, including the sale of the Obagi Japan trademark and refinancing of credit facilities, aim to strengthen its balance sheet amid a competitive beauty market.
What we're watching
- Brand Performance
- How Obagi Medical's expansion into medical aesthetics will impact its revenue growth.
- Market Dynamics
- Whether Milk Makeup can recover from softer international consumption through focused investments.
- Strategic Review
- The potential outcomes of Waldencast's strategic review and its impact on shareholder value.
Related topics